Skip to main content

Table 3 Multivariable analysis of the differences between reclassified or not reclassified patients

From: Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk

  Not reclassified (n = 684) Reclassified (n = 578) p Reclassification
OR (95% CI), p*
cIMT, μm 650 ± 140 740 ± 140 0.000  
Age, years 54 ± 14 62 ± 9 0.000  
Female, n (%) 531 (78) 437 (76) 0.40  
BMI, kg/m2 27 ± 6 28 ± 5 0.39  
Abdominal circumference, cm 94 ± 15 94 ± 14 0.92  
Cardiovascular data
 CV risk factors, n (%)
  Current smoker 169 (25) 153 (26) 0.47  
  Obesity 193 (28) 155 (27) 0.58  
  Dyslipidemia 275 (40) 332 (57) 0.000  
  Hypertension 192 (28) 271 (47) 0.000  
 Blood pressure, mmHg
  Systolic 130 ± 18 132 ± 16 0.024  
  Diastolic 78 ± 10 79 ± 9 0.58  
 Lipids
  Total cholesterol, mmol/l 5.26 ± 0.96 5.28 ± 0.96 0.66  
  Triglycerides, mmol/l 1.24 ± 0.71 1.28 ± 0.68 0.35  
  HDL cholesterol, mmol/l 1.58 ± 0.44 1.58 ± 0.44 0.90  
  LDL cholesterol, mmol/l 3.10 ± 0.80 3.10 ± 0.83 0.94  
  Atherogenic index 3.56 ± 1.11 3.53 ± 0.97 0.63  
 Statins, n (%) 113 (17) 188 (33) 0.000  
 Aspirin, n (%) 16 (2) 27 (5) 0.018  
 Antihypertensive treatment, n (%) 140 (20) 190 (33) 0.000  
Disease-related data
 Disease duration, years 5 (2–12) 5 (2–12) 0.62  
 CRP at time of study, mg/l 2.5 (0.9–6.4) 3.0 (1.0–7.0) 0.71  
 ESR at time of study, mm/ 1° hour 11 (5 − 21) 13 (6–25) 0.007 1.00 (0.99–1.01), 0.79
 Rheumatoid factor, n (%) 380 (56) 360 (62) 0.019 1.58 (1.19–2.11), 0.002
 ACPA, n (%) 352 (51) 320 (55) 0.097 1.46 (1.09–1.94), 0.011
 DAS28-ESR 2.96 ± 1.50 3.27 ± 1.46 0.000 1.09 (1.02–1.19), 0.028
 DAS28-PCR 2.91 ± 1.28 3.10 ± 1.28 0.010 1.04 (0.93–1.16), 0.095
 SDAI 3.20 ± 2.05 3.10 ± 2.02 0.73  
 CDAI 8 (3–16) 9 (4–17) 0.078 1.00 (0.99–1.02), 0.52
 HAQ 0.690 (0250–1.250) 0.750 (0250–1.250) 0.36  
 RAPID 3.20 ± 2.05 3.10 ± 2.02 0.61  
 Current drugs, n (%)
  Prednisone 330 (48) 291 (50) 0.46  
  Prednisone doses, mg/day 5 (2.5–6) 5 (5–7.5) 0.42  
  NSAIDs 282 (41) 205 (35) 0.036 0.93 (0.70–1.24), 0.62
  DMARDs 525 (77) 444 (77) 0.98  
  Methotrexate 395 (58) 324 (56) 0.55  
  Leflunomide 70 (10) 68 (12) 0.39  
  Hydroxychloroquine 147 (21) 132 (23) 0.57  
  Sulphasalazine 19 (3) 24 (4) 0.18 1.69 (0.84–3.41), 0.15
  Anti-TNF therapy 91 (13) 72 (12) 0.66  
   Adalimumab 26 (4) 28 (5) 0.36  
   Infliximab 12 (2) 6 (1) 0.29  
   Etanercept 40 (6) 26 (4) 0.28  
   Golimumab 1 (0) 3 (1) 0.34  
  Tocilizumab 37 (5) 27 (5) 0.56  
  Rituximab 9 (1) 11 (2) 0.40  
  Abatacept 8 (1) 13 (2) 0.14 2.13 (0.77–5.97), 0.15
  Baricitinib 5 (1) 6 (1) 0.56  
  Tofacitinib 9 (1) 5 (1) 0.45  
Historical disease-related data
 History of extraarticular manif., n (%) 112 (16) 119 (21) 0.058 1.07 (0.75–1.52), 0.72
 Erosions, n (%) 230 (34) 216 (37) 0.048 1.26 (0.93–1.72), 0.13
 CRP at time of disease diagnosis, mg/l 7 (2–19) 8 (3–22) 0.28  
 CRP > 3 at time of diagnosis, n (%) 354 (52) 324 (56) 0.068 1.13 (0.78–1.64), 0.52
 ESR at the time of diagnosis, mm/1st hour 20 (11–37) 23 (12–40) 0.28  
  1. Data represent means ± SD or median (IQR) when data were not normally distributed
  2. CV cardiovascular, LDL low-density lipoprotein, HDL high-density lipoprotein, CRP C-reactive protein, NSAID nonsteroidal anti-inflammatory drugs, DMARD disease-modifying antirheumatic drug, TNF tumor necrosis factor, obesity, ESR erythrocyte sedimentation rate, BMI body mass index, DAS28 Disease Activity Score in 28 joints, ACPA anti-citrullinated protein antibodies, RAPID routine assessment of patient index, CDAI Clinical Disease Activity Index, SDAI Simple Disease Activity Index, HAQ Health Assessment Questionnaire
  3. *Multivariable analysis is adjusted for age, dyslipidemia, hypertension, and statins and aspirin intake